Tesamorelin
A compound that copies the action of a hormone that signals the release of growth hormone. It has been studied in medicinal products.
Whole vial: 10 mg Vial math ↓
Why people look it up
Tesamorelin is known because an approved prescription product reduces excess abdominal fat in adults with HIV-associated lipodystrophy. People also discuss it for general body composition.
Excess abdominal fat in adults with HIV lipodystrophyFDA-APPROVED USE
EGRIFTA WR is approved for this defined population and outcome, not this dry vial. Read source ↗
Applies to the named prescription product, not this research vial.
Growth-hormone signalingHUMAN CLINICAL EVIDENCE
The prescription-product label describes its growth-hormone-releasing action in studied people. Read source ↗
General weight lossINSUFFICIENT EVIDENCE
The product label specifically says it is not indicated for weight-loss management. Read source ↗
The labels show the evidence for each claim. Open a row for its source.
Dosage at a glance
Dosage source summary
- How often
- Once daily
- Time on / time off
- A fixed labeled dose; no low/middle/high bands.
- Route
- Subcutaneous manufactured prescription product.
Applies to the EGRIFTA WR 11.6 mg prescription formulation. Other formulations are not substitutable; this is not a dry 10 mg vial protocol.
These source amounts do not establish a safe human dose for a research vial.
Sources & individual reports
Applies to the EGRIFTA WR 11.6 mg prescription formulation. Other formulations are not substitutable; this is not a dry 10 mg vial protocol. Source check: 2026-10-18.
Source coverage: 1 reviewed public account. Not a community consensus.
Report 1 ↗First-person account
- Amount reported
- eventually about 1.2–1.5 mg tesamorelin with about 350 mcg ipamorelin
- How often reported
- not stated
- Reported duration / cycle
- about seven to eight weeks
- Route (how it was taken)
- not stated
What the account says: Poster used two compounds together, described arm and hand numbness and tingling, and stopped. This cannot isolate tesamorelin effects.
Product match & source details
Product match: Not a report about the named finished prescription product or this research vial.
r/Biohacking firsthand post · Posted: date not independently verified · Reviewed: 2026-10-03.
How much agreement is there? Only one directly checked account is shown. Do not substitute it for the prescription-product label or a matched research-vial schedule.
Public sources last reviewed: 2026-10-03. Product identity and reported results were not independently verified. Source method →
Evidence, sources & vial math
What the research actually showsHuman studies, evidence limits and mechanisms
What has actually been studied?
EGRIFTA WR has a specific FDA-approved indication. Its label states it is not indicated for weight-loss management; clinical findings do not validate a research vial.
Evidence limits: EGRIFTA WR evidence applies to its specific formulation and population, not this research vial. Product-specific preparation and safety remain unverified.
Product status: Research-vial listings are not FDA-approved medicines. Approved-use labels on this page refer only to the named finished prescription product.
Human research
Tesamorelin and visceral fat in people with HIV 2007
What was found: Visceral fat decreased 15.2% in the tesamorelin arm and increased 5.0% in the placebo arm.
Main limit: The original trial formulation and 2 mg amount are different from the current EGRIFTA WR label amount. Neither establishes a regimen for this research vial or general weight loss.
Study setup and amounts
- Who
- Adults with HIV and treatment-associated excess abdominal fat
- Number of participants
- 412
- Study design
- Randomized placebo-controlled clinical trial
- Route
- Subcutaneous study product
- Amount studied
- 2 mg in the original trial formulation
- Frequency
- Daily
- Duration
- 26 weeks
- Outcome measured
- Change in visceral adipose tissue measured by CT
Study and prescription-product amounts describe those sources. They do not select an amount for an online research vial.
How researchers think it might work
Tesamorelin imitates a hormone signal that tells the pituitary to release growth hormone. The studied prescription product has a specific use and formulation.
Show scientific explanation
The EGRIFTA WR label states that tesamorelin stimulates human growth-hormone-releasing-factor receptors in vitro and increases growth hormone and IGF-1 signaling. That label does not establish properties of this separate research vial. Read supporting source ↗
Vial & syringe mathTurn the vial total and liquid volume into concentration and syringe units
Vial & syringe math
Change the vial total and final liquid volume to see what each U-100 syringe mark represents.
The starting 1 mL is a math example. Enter your final mixed volume to update the numbers.
100 U-100 syringe units = 1 mL. These results assume the labeled amount is evenly mixed through the final liquid volume.
See source amounts as syringe units
Prescription product label. The 1.28 mg amount applies to EGRIFTA WR, an 11.6 mg prescription formulation for a specific approved use. Its label says that formulation differs from EGRIFTA SV. Neither label supplies directions for this separate 10 mg research vial. Read the EGRIFTA WR prescribing information ↗
| Source row | Amount | Liquid volume | U-100 units | Full amounts in one vial* |
|---|---|---|---|---|
| EGRIFTA WR label amount | 1.28 mg | — | — | — |
*Whole amounts by mass, before handling loss. Flags identify amounts above the vial total, volumes above the 100-unit scale, or measurements below one unit. Source amounts describe the named product or study; they do not choose an amount for a research vial.
About this listingResearch-use-only status, seller names and additional background
A research material is not intended for human use. Its name or lab report does not establish suitability for a person. What research use only means →
Compiled by PeptideWhy · Scientific sources last checked 2026-10-03 · Editorial policy · Corrections